Ajanta Pharma Ltd
AJANTPHARMAjanta Pharma Ltd
AJANTPHARM
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 46.79 | 11.20 | 1.62% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.06 | 6.53 | 0.48% |
Forecast & Ratings
Detailed Forecast from 11 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Ajanta Pharma Limited is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,770.52 | 2,007.12 | 2,149.92 | 2,076.45 | 2,680.06 | 2,915.67 | 3,456.67 | 3,841.28 | 4,293.31 | 4,429.48 | ||||||||||
Raw Materials | 463.10 | 425.21 | 455.63 | 440.09 | 672.46 | 795.95 | 915.44 | 1,024.64 | 1,105.78 | 3,119.19 | ||||||||||
| Power & Fuel Cost | 15.49 | 18.70 | 27.42 | 32.65 | 38.88 | 43.70 | 54.38 | 65.71 | 66.57 | |||||||||||
| Employee Cost | 256.64 | 295.42 | 376.47 | 430.71 | 485.59 | 548.25 | 645.78 | 785.14 | 900.34 | |||||||||||
| Selling & Administrative Expenses | 327.55 | 362.94 | 424.71 | 445.52 | 534.89 | 484.01 | 652.72 | 784.97 | 749.71 | |||||||||||
| Operating & Other expenses | 99.53 | 194.11 | 183.14 | 139.97 | 176.64 | 19.22 | 143.37 | 298.93 | 214.37 | |||||||||||
EBITDA | 608.21 | 710.74 | 682.55 | 587.51 | 771.60 | 1,024.54 | 1,044.98 | 881.89 | 1,256.54 | 1,310.29 | ||||||||||
| Depreciation/Amortization | 44.43 | 61.21 | 59.59 | 72.08 | 95.72 | 116.09 | 125.30 | 130.80 | 135.40 | 136.19 | ||||||||||
| PBIT | 563.78 | 649.53 | 622.96 | 515.43 | 675.88 | 908.45 | 919.68 | 751.09 | 1,121.14 | 1,174.10 | ||||||||||
| Interest & Other Items | 4.89 | 1.36 | 0.41 | 1.16 | 11.91 | 8.27 | 10.20 | 5.84 | 7.21 | 7.09 | ||||||||||
| PBT | 558.89 | 648.17 | 622.55 | 514.27 | 663.97 | 900.18 | 909.48 | 745.25 | 1,113.93 | 1,167.01 | ||||||||||
| Taxes & Other Items | 143.28 | 141.34 | 153.91 | 127.30 | 196.27 | 246.31 | 196.80 | 157.27 | 297.76 | 313.19 | ||||||||||
| Net Income | 415.61 | 506.83 | 468.64 | 386.97 | 467.70 | 653.87 | 712.68 | 587.98 | 816.17 | 853.82 | ||||||||||
| EPS | 31.36 | 38.23 | 35.19 | 29.18 | 35.42 | 49.73 | 54.78 | 45.94 | 64.43 | 67.40 | ||||||||||
| DPS | 5.33 | 8.67 | 0.00 | 6.00 | 8.67 | 6.33 | 6.33 | 7.00 | 51.00 | 51.00 | ||||||||||
| Payout ratio | 0.17 | 0.23 | 0.00 | 0.21 | 0.24 | 0.13 | 0.12 | 0.15 | 0.79 | 0.76 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Ajanta Pharma Ltd | 48.95 | 11.20 | 1.62% |
| Sun Pharmaceutical Industries Ltd | 46.25 | 6.60 | 0.73% |
| Cipla Ltd | 32.09 | 4.93 | 0.79% |
| Torrent Pharmaceuticals Ltd | 68.49 | 16.55 | 0.84% |
Price Comparison
Compare AJANTPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Ajanta Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Nippon India Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.4485% | Percentage of the fund’s portfolio invested in the stock 0.95% | Change in the portfolio weight of the stock over the last 3 months 0.23% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/231 (+12) |
UTI Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.1924% | Percentage of the fund’s portfolio invested in the stock 1.76% | Change in the portfolio weight of the stock over the last 3 months 0.41% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/68 (+1) |
Kotak Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7933% | Percentage of the fund’s portfolio invested in the stock 1.81% | Change in the portfolio weight of the stock over the last 3 months 0.46% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/80 (+13) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Ajanta Pharma Ltd
Events
Dividend Trend
Dividend Yield
Current dividend yield is 1.66%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹16.57 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 8, 2024
Dividend/Share
₹26.00
Ex DateEx Date
Feb 8, 2024
Cash Dividend
Ex DateEx DateAug 4, 2023
Dividend/Share
₹10.00
Ex DateEx Date
Aug 4, 2023
Cash Dividend
Ex DateEx DateAug 4, 2023
Dividend/Share
₹15.00
Ex DateEx Date
Aug 4, 2023
Cash Dividend
Ex DateEx DateNov 11, 2022
Dividend/Share
₹7.00
Ex DateEx Date
Nov 11, 2022
Cash Dividend
Ex DateEx DateNov 9, 2021
Dividend/Share
₹9.50
Ex DateEx Date
Nov 9, 2021
Technical Breakout Stocks: Sun Pharma, Ajanta Pharma and JB Chemicals hit record high when Sensex falls 2,200 points - Market Roundup
Ajanta Pharma among 2 stocks with White Marubozu Pattern
Ajanta Pharma Q1 results: PAT up 18% to Rs 246 cr on robust sales
Ajanta Pharma consolidated net profit rises 18.09% in the June 2024 quarter
Net profit of Ajanta Pharma rose 18.09% to Rs 245.77 crore in the quarter ended June 2024 as against Rs 208.12 crore during the previous quarter ended June 2023. Sales rose 12.13% to Rs 1144.92 crore in the quarter ended June 2024 as against Rs 1021.04 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1144.921021.04 12 OPM %28.8526.57 - PBDT356.09302.22 18 PBT322.12269.04 20 NP245.77208.12 18 Powered by Capital Market - Live
Ajanta Pharma hits record high after Q1 PAT rises 19% YoY to Rs 246 cr
Profit before tax increased 19.73% YoY to Rs 322.12 crore in Q1 FY25. EBITDA stood at Rs 330 crore in Q1 FY25, up 22% as against 271 crore posted in same quarter last year. EBITDA margin was at 29% in Q1 FY25 as against 27% in Q1 FY24. During the quarter, the company's revenue from India stood at Rs 353 crore (up 10% YoY), revenue from Asia was at Rs 277 crore ( up 9% YoY), income from Africa stood at Rs 230 crore (up 45% YoY) while revenue from United States was at Rs 228 crore ( up 7% YoY). Research and development (R&D) expenses were at Rs 51 crore in Q1 FY25, 4.50% of revenue. Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified branded generics business spread across India, the Rest of Asia, and Africa. The company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. The scrip hit an all-time high at Rs 2576.25 in intraday today.Powered by Capital Market - Live
Stock to buy today: Ajanta Pharma (₹2,291.05)
Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 July 2024.Powered by Capital Market - Live
Ajanta Pharma - Investments In Branded Generics Added Certainty, Scalability, Sustainability: Dolat Capital
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 15.64%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.95% to 1.14%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 16.1%, vs industry avg of 15.28%